CeriBell, Inc. (NASDAQ:CBLL) Sees Significant Decrease in Short Interest

CeriBell, Inc. (NASDAQ:CBLL) was the target of a significant drop in short interest in April. As of April 15th, there was short interest totaling 1,530,162 shares, a drop of 18.6% from the March 31st total of 1,880,159 shares. Based on an average daily trading volume, of 249,548 shares, the days-to-cover ratio is currently 6.1 days. Approximately 5.1% of the company’s stock are short sold.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. BTIG Research reaffirmed a “buy” rating and set a $30.00 price objective on shares of CeriBell in a research report on Wednesday, January 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CeriBell in a research note on Monday, April 6th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, CeriBell has a consensus rating of “Moderate Buy” and an average price target of $23.20.

Insider Activity

In related news, Director Josef Parvizi sold 16,714 shares of CeriBell stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $20.27, for a total transaction of $338,792.78. Following the completion of the transaction, the director owned 722,652 shares in the company, valued at approximately $14,648,156.04. This trade represents a 2.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Xingjuan Chao sold 39,000 shares of CeriBell stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $17.45, for a total value of $680,550.00. Following the transaction, the chief executive officer owned 711,164 shares of the company’s stock, valued at $12,409,811.80. The trade was a 5.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 130,571 shares of company stock valued at $2,411,026 over the last three months. Corporate insiders own 20.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Strs Ohio bought a new position in shares of CeriBell in the 1st quarter worth about $27,000. Caitong International Asset Management Co. Ltd increased its position in CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after buying an additional 1,231 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in CeriBell during the 3rd quarter valued at $33,000. CWM LLC increased its stake in CeriBell by 1,178.5% during the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after purchasing an additional 1,697 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after purchasing an additional 1,801 shares in the last quarter.

CeriBell Price Performance

Shares of CBLL stock traded up $0.81 on Thursday, reaching $20.06. The company had a trading volume of 126,233 shares, compared to its average volume of 310,227. CeriBell has a one year low of $10.85 and a one year high of $24.33. The stock has a market capitalization of $759.71 million, a PE ratio of -13.60 and a beta of 0.94. The company has a quick ratio of 9.35, a current ratio of 9.73 and a debt-to-equity ratio of 0.13. The business’s 50-day moving average is $19.16 and its 200 day moving average is $18.45.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. CeriBell had a negative return on equity of 31.77% and a negative net margin of 59.97%.The company had revenue of $24.78 million during the quarter, compared to analysts’ expectations of $23.95 million. Equities research analysts forecast that CeriBell will post -1.44 EPS for the current fiscal year.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.